The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
Swetha Rao Palli,1 Michael Grabner,1 Ralph A Quimbo,1 Hope S Rugo2 1HealthCore, Wilmington, DE, 2University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA Purpose: To determine the incidence of chemotherapy-induced nausea/vomiting (CINV) and chem...
Main Authors: | Palli SR, Grabner M, Quimbo RA, Rugo HS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-06-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/the-impact-of-5-hydroxytryptamine-receptor-antagonists-on-chemotherapy-peer-reviewed-article-CMAR |
Similar Items
-
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study
by: Reiko Matsui, et al.
Published: (2020-10-01) -
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
by: Rudolph M. Navari
Published: (2015-01-01) -
The assessment and treatment of nausea and vomiting associated with cancer chemotherapy
by: Rosberger, Zeev
Published: (1988) -
Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy
by: Monique Sedlmaier França, et al. -
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
by: Navari RM, et al.
Published: (2018-10-01)